{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,18]],"date-time":"2026-11-18T18:52:55Z","timestamp":1795027975442,"version":"4.10.2"},"reference-count":28,"publisher":"American Society of Hematology","issue":"14","content-domain":{"domain":["ashpublications.org"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2021,7,27]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>The Endothelial Activation and Stress Index (EASIX) score, defined as [(creatinine \u00d7 lactate dehydrogenase [LDH])\/platelets], is a marker of endothelial activation that has been validated in the allogeneic hematopoietic stem cell transplant setting. Endothelial activation is one of the mechanisms driving immune-mediated toxicities in patients treated with chimeric antigen receptor-T (CAR-T)-cell therapy. This study\u2019s objective was to evaluate the association between EASIX and other laboratory parameters collected before lymphodepletion and the subsequent onset of cytokine release syndrome (CRS) and immune effector cell\u2013associated neurotoxicity syndrome (ICANS) those patients. Toxicity data were collected prospectively on 171 patients treated with axicabtagene ciloleucel (axi-cel) for large B-cell lymphoma (LBCL). CRS grades 2 to 4 were diagnosed in 81 (47%) patients and ICANS grades 2 to 4 in 84 (49%). EASIX combined with ferritin (EASIX-F) identified 3 risk groups with CRS grades 2 to 4 cumulative incidence of 74% (hazards ratio [HR], 4.8; 95% confidence interval [CI], 2.1-11; P &amp;lt; .001), 49% (HR, 2.3; 95% CI, 1.02-5; P = .04), and 23% (reference), respectively. EASIX combined with CRP and ferritin (EASIX-FC) identified 3 risk groups with an ICANS grade 2 to 4 cumulative incidence of 74% (HR, 3.6; 95% CI, 1.9-6.9; P &amp;lt; .001), 51% (HR, 2.1; 95% CI, 1.1-3.9; P = .025), and 29% (reference). Our results indicate that common laboratory parameters before lymphodepletion correlate with CAR-T\u2013related toxicities and can help support clinical decisions, such as preemptive toxicity management, hospitalization length, and proper setting for CAR-T administration.<\/jats:p>","DOI":"10.1182\/bloodadvances.2021004575","type":"journal-article","created":{"date-parts":[[2021,7,15]],"date-time":"2021-07-15T11:33:52Z","timestamp":1626348832000},"page":"2799-2806","update-policy":"https:\/\/doi.org\/10.1182\/blood.2019cm0000","source":"Crossref","is-referenced-by-count":156,"title":["CRP and ferritin in addition to the EASIX score predict CAR-T\u2013related toxicity"],"prefix":"10.1182","volume":"5","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-8582-4572","authenticated-orcid":false,"given":"Uri","family":"Greenbaum","sequence":"first","affiliation":[{"name":"Department of Stem Cell Transplantation and Cellular Therapy,"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paolo","family":"Strati","sequence":"additional","affiliation":[{"name":"Department of Lymphoma and Myeloma,"},{"name":"Department of Translational Molecular Pathology,"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rima M.","family":"Saliba","sequence":"additional","affiliation":[{"name":"Department of Stem Cell Transplantation and Cellular Therapy,"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Janet","family":"Torres","sequence":"additional","affiliation":[{"name":"Department of Stem Cell Transplantation and Cellular Therapy,"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gabriela","family":"Rondon","sequence":"additional","affiliation":[{"name":"Department of Stem Cell Transplantation and Cellular Therapy,"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6034-8939","authenticated-orcid":false,"given":"Yago","family":"Nieto","sequence":"additional","affiliation":[{"name":"Department of Stem Cell Transplantation and Cellular Therapy,"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chitra","family":"Hosing","sequence":"additional","affiliation":[{"name":"Department of Stem Cell Transplantation and Cellular Therapy,"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Samer A.","family":"Srour","sequence":"additional","affiliation":[{"name":"Department of Stem Cell Transplantation and Cellular Therapy,"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1824-2337","authenticated-orcid":false,"given":"Jason","family":"Westin","sequence":"additional","affiliation":[{"name":"Department of Lymphoma and Myeloma,"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Luis E.","family":"Fayad","sequence":"additional","affiliation":[{"name":"Department of Lymphoma and Myeloma,"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hun J.","family":"Lee","sequence":"additional","affiliation":[{"name":"Department of Lymphoma and Myeloma,"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Swaminathan P.","family":"Iyer","sequence":"additional","affiliation":[{"name":"Department of Lymphoma and Myeloma,"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ranjit","family":"Nair","sequence":"additional","affiliation":[{"name":"Department of Lymphoma and Myeloma,"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Loretta J.","family":"Nastoupil","sequence":"additional","affiliation":[{"name":"Department of Lymphoma and Myeloma,"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Simrit","family":"Parmar","sequence":"additional","affiliation":[{"name":"Department of Lymphoma and Myeloma,"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3564-8697","authenticated-orcid":false,"given":"Maria A.","family":"Rodriguez","sequence":"additional","affiliation":[{"name":"Department of Lymphoma and Myeloma,"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Felipe","family":"Samaniego","sequence":"additional","affiliation":[{"name":"Department of Lymphoma and Myeloma,"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3717-3629","authenticated-orcid":false,"given":"Raphael E.","family":"Steiner","sequence":"additional","affiliation":[{"name":"Department of Lymphoma and Myeloma,"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9748-5486","authenticated-orcid":false,"given":"Michael","family":"Wang","sequence":"additional","affiliation":[{"name":"Department of Lymphoma and Myeloma,"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chelsea C.","family":"Pinnix","sequence":"additional","affiliation":[{"name":"Department of Radiation Oncology, and"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christopher R.","family":"Flowers","sequence":"additional","affiliation":[{"name":"Department of Lymphoma and Myeloma,"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sudhakar","family":"Tummala","sequence":"additional","affiliation":[{"name":"Department of Neuro-oncology, University of Texas MD Anderson Cancer Center, Houston, TX"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jeremy L.","family":"Ramdial","sequence":"additional","affiliation":[{"name":"Department of Stem Cell Transplantation and Cellular Therapy,"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3569-8632","authenticated-orcid":false,"given":"Fevzi F.","family":"Yalniz","sequence":"additional","affiliation":[{"name":"Department of Stem Cell Transplantation and Cellular Therapy,"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Misha","family":"Hawkins","sequence":"additional","affiliation":[{"name":"Department of Lymphoma and Myeloma,"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Katayoun","family":"Rezvani","sequence":"additional","affiliation":[{"name":"Department of Stem Cell Transplantation and Cellular Therapy,"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4314-5037","authenticated-orcid":false,"given":"Richard E.","family":"Champlin","sequence":"additional","affiliation":[{"name":"Department of Stem Cell Transplantation and Cellular Therapy,"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elizabeth J.","family":"Shpall","sequence":"additional","affiliation":[{"name":"Department of Stem Cell Transplantation and Cellular Therapy,"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1045-4914","authenticated-orcid":false,"given":"Sattva S.","family":"Neelapu","sequence":"additional","affiliation":[{"name":"Department of Lymphoma and Myeloma,"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Partow","family":"Kebriaei","sequence":"additional","affiliation":[{"name":"Department of Stem Cell Transplantation and Cellular Therapy,"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7302-8299","authenticated-orcid":false,"given":"Sairah","family":"Ahmed","sequence":"additional","affiliation":[{"name":"Department of Stem Cell Transplantation and Cellular Therapy,"},{"name":"Department of Lymphoma and Myeloma,"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"234","published-online":{"date-parts":[[2021,7,15]]},"reference":[{"issue":"26","key":"2021071515334678400_B1","doi-asserted-by":"crossref","first-page":"2531","DOI":"10.1056\/NEJMoa1707447","article-title":"Axicabtagene Ciloleucel CAR T-Cell Therapy in Refractory Large B-Cell Lymphoma","volume":"377","author":"Neelapu","year":"2017","journal-title":"N Engl J Med."},{"issue":"10254","key":"2021071515334678400_B2","doi-asserted-by":"crossref","first-page":"839","DOI":"10.1016\/S0140-6736(20)31366-0","article-title":"Lisocabtagene maraleucel for patients with relapsed or refractory large B-cell lymphomas (TRANSCEND NHL 001): a multicentre seamless design study","volume":"396","author":"Abramson","year":"2020","journal-title":"Lancet."},{"issue":"3","key":"2021071515334678400_B3","doi-asserted-by":"crossref","first-page":"S20","DOI":"10.1016\/j.bbmt.2018.12.089","article-title":"Long-Term Follow-up of Tisagenlecleucel in Adult Patients with Relapsed or Refractory Diffuse Large B-Cell Lymphoma: Updated Analysis of Juliet Study","volume":"25","author":"Schuster","year":"2019","journal-title":"Biol Blood Marrow Transplant."},{"issue":"21","key":"2021071515334678400_B4","doi-asserted-by":"crossref","first-page":"2295","DOI":"10.1182\/blood-2017-06-793141","article-title":"Kinetics and biomarkers of severe cytokine release syndrome after CD19 chimeric antigen receptor-modified T-cell therapy","volume":"130","author":"Hay","year":"2017","journal-title":"Blood."},{"issue":"16","key":"2021071515334678400_B5","doi-asserted-by":"crossref","first-page":"3943","DOI":"10.1182\/bloodadvances.2020002228","article-title":"Clinical and radiologic correlates of neurotoxicity after axicabtagene ciloleucel in large B-cell lymphoma","volume":"4","author":"Strati","year":"2020","journal-title":"Blood Adv."},{"issue":"12","key":"2021071515334678400_B6","doi-asserted-by":"crossref","first-page":"1536","DOI":"10.1001\/jamaneurol.2020.2703","article-title":"Clinical Predictors of Neurotoxicity After Chimeric Antigen Receptor T-Cell Therapy","volume":"77","author":"Rubin","year":"2020","journal-title":"JAMA Neurol."},{"issue":"27","key":"2021071515334678400_B7","doi-asserted-by":"crossref","first-page":"3119","DOI":"10.1200\/JCO.19.02104","article-title":"Standard-of-Care Axicabtagene Ciloleucel for Relapsed or Refractory Large B-Cell Lymphoma: Results From the US Lymphoma CAR T Consortium","volume":"38","author":"Nastoupil","year":"2020","journal-title":"J Clin Oncol."},{"issue":"19","key":"2021071515334678400_B8","doi-asserted-by":"crossref","first-page":"4898","DOI":"10.1182\/bloodadvances.2020002394","article-title":"Tumor burden, inflammation, and product attributes determine outcomes of axicabtagene ciloleucel in large B-cell lymphoma","volume":"4","author":"Locke","year":"2020","journal-title":"Blood Adv."},{"issue":"12","key":"2021071515334678400_B9","doi-asserted-by":"crossref","first-page":"1404","DOI":"10.1158\/2159-8290.CD-17-0698","article-title":"Endothelial Activation and Blood-Brain Barrier Disruption in Neurotoxicity after Adoptive Immunotherapy with CD19 CAR-T Cells","volume":"7","author":"Gust","year":"2017","journal-title":"Cancer Discov."},{"issue":"1","key":"2021071515334678400_B10","doi-asserted-by":"crossref","first-page":"e487","DOI":"10.1097\/HS9.0000000000000487","article-title":"Endothelial and Complement Activation As Predictors of Survival in Adult Allogeneic Hematopoietic Cell Transplantation [letter]","volume":"5","author":"Gavriilaki","year":"2021","journal-title":"HemaSphere."},{"issue":"5","key":"2021071515334678400_B11","doi-asserted-by":"crossref","first-page":"1013","DOI":"10.1016\/j.bbmt.2020.01.028","article-title":"Endothelial Activation and Stress Index (EASIX) at Admission Predicts Fluid Overload in Recipients of Allogeneic Stem Cell Transplantation","volume":"26","author":"Varma","year":"2020","journal-title":"Biol Blood Marrow Transplant."},{"issue":"2","key":"2021071515334678400_B12","doi-asserted-by":"crossref","first-page":"446","DOI":"10.3324\/haematol.2019.238790","article-title":"Predicting sinusoidal obstruction syndrome after allogeneic stem cell transplantation with the EASIX biomarker panel","volume":"106","author":"Jiang","year":"2021","journal-title":"Haematologica."},{"issue":"3","key":"2021071515334678400_B13","doi-asserted-by":"crossref","first-page":"553","DOI":"10.1038\/s41409-019-0703-1","article-title":"EASIX and mortality after allogeneic stem cell transplantation","volume":"55","author":"Luft","year":"2020","journal-title":"Bone Marrow Transplant."},{"issue":"9","key":"2021071515334678400_B14","doi-asserted-by":"crossref","first-page":"e414","DOI":"10.1016\/S2352-3026(17)30108-4","article-title":"EASIX in patients with acute graft-versus-host disease: a retrospective cohort analysis","volume":"4","author":"Luft","year":"2017","journal-title":"Lancet Haematol."},{"issue":"1","key":"2021071515334678400_B15","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1038\/nrclinonc.2017.148","article-title":"Chimeric antigen receptor T-cell therapy - assessment and management of toxicities","volume":"15","author":"Neelapu","year":"2018","journal-title":"Nat Rev Clin Oncol."},{"issue":"4","key":"2021071515334678400_B16","doi-asserted-by":"crossref","first-page":"625","DOI":"10.1016\/j.bbmt.2018.12.758","article-title":"ASTCT Consensus Grading for Cytokine Release Syndrome and Neurologic Toxicity Associated with Immune Effector Cells","volume":"25","author":"Lee","year":"2019","journal-title":"Biol Blood Marrow Transplant."},{"issue":"6","key":"2021071515334678400_B17","doi-asserted-by":"crossref","first-page":"649","DOI":"10.1097\/00000421-198212000-00014","article-title":"Toxicity and response criteria of the Eastern Cooperative Oncology Group","volume":"5","author":"Oken","year":"1982","journal-title":"Am J Clin Oncol."},{"issue":"5","key":"2021071515334678400_B18","doi-asserted-by":"crossref","first-page":"1857","DOI":"10.1182\/blood-2006-08-038257","article-title":"The revised International Prognostic Index (R-IPI) is a better predictor of outcome than the standard IPI for patients with diffuse large B-cell lymphoma treated with R-CHOP","volume":"109","author":"Sehn","year":"2007","journal-title":"Blood."},{"issue":"6","key":"2021071515334678400_B19","doi-asserted-by":"crossref","first-page":"731","DOI":"10.1038\/s41591-018-0041-7","article-title":"CAR T cell-induced cytokine release syndrome is mediated by macrophages and abated by IL-1 blockade","volume":"24","author":"Giavridis","year":"2018","journal-title":"Nat Med."},{"issue":"6","key":"2021071515334678400_B20","doi-asserted-by":"crossref","first-page":"739","DOI":"10.1038\/s41591-018-0036-4","article-title":"Monocyte-derived IL-1 and IL-6 are differentially required for cytokine-release syndrome and neurotoxicity due to CAR T cells","volume":"24","author":"Norelli","year":"2018","journal-title":"Nat Med."},{"issue":"36","key":"2021071515334678400_B21","doi-asserted-by":"crossref","first-page":"22351","DOI":"10.1073\/pnas.2010229117","article-title":"IL-6 trans-signaling induces plasminogen activator inhibitor-1 from vascular endothelial cells in cytokine release syndrome","volume":"117","author":"Kang","year":"2020","journal-title":"Proc Natl Acad Sci USA."},{"issue":"6","key":"2021071515334678400_B22","doi-asserted-by":"crossref","first-page":"750","DOI":"10.1158\/2159-8290.CD-17-1368","article-title":"Chimeric Antigen Receptor T Cell-Mediated Neurotoxicity in Nonhuman Primates","volume":"8","author":"Taraseviciute","year":"2018","journal-title":"Cancer Discov."},{"key":"2021071515334678400_B23","doi-asserted-by":"crossref","first-page":"307","DOI":"10.1002\/hon.117_2630","article-title":"Cytokine release syndrome and neurotoxicity by baseline tumor burden in adults with relapsed or refractory diffuse large B-cell lymphoma treated with tisagenlecleucel [abstract]","volume":"37","author":"Maziarz","year":"2019","journal-title":"Hematol Oncol."},{"issue":"2","key":"2021071515334678400_B24","doi-asserted-by":"crossref","first-page":"e001511","DOI":"10.1136\/jitc-2020-001511","article-title":"Society for Immunotherapy of Cancer (SITC) clinical practice guideline on immune effector cell-related adverse events","volume":"8","author":"Maus","year":"2020","journal-title":"J Immunother Cancer."},{"key":"2021071515334678400_B25","doi-asserted-by":"crossref","DOI":"10.1182\/blood-2019-126208","article-title":"Easix and modified-Easix are early predictors of severe cytokine release syndrome and neurotoxicity in patients treated with chimeric antigen receptor T cells [abstract]","volume":"134","author":"Pennisi","year":"2019","journal-title":"Blood."},{"key":"2021071515334678400_B26","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1182\/blood-2020-139615","article-title":"Easix as prediction score before CAR-T cells Vs allogeneic hematopoietic cell transplantation (alloHCT) for relapsed\/refractory (r\/r) large B cell lymphoma (LBCL) [abstract]","volume":"136","author":"Korell","year":"2020","journal-title":"Blood."},{"issue":"14","key":"2021071515334678400_B27","doi-asserted-by":"crossref","first-page":"3268","DOI":"10.1182\/bloodadvances.2020001900","article-title":"High metabolic tumor volume is associated with decreased efficacy of axicabtagene ciloleucel in large B-cell lymphoma","volume":"4","author":"Dean","year":"2020","journal-title":"Blood Adv."},{"issue":"8","key":"2021071515334678400_B28","doi-asserted-by":"crossref","first-page":"920","DOI":"10.1200\/JCO.20.02477","article-title":"Risk-Adapted Preemptive Tocilizumab to Prevent Severe Cytokine Release Syndrome After CTL019 for Pediatric B-Cell Acute Lymphoblastic Leukemia: A Prospective Clinical Trial","volume":"39","author":"Kadauke","year":"2021","journal-title":"J Clin Oncol."}],"updated-by":[{"DOI":"10.1182\/bloodadvances.2025018619","type":"erratum","label":"Erratum","source":"publisher","updated":{"date-parts":[[2025,12,23]],"date-time":"2025-12-23T00:00:00Z","timestamp":1766448000000}}],"container-title":["Blood Advances"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/ashpublications.org\/bloodadvances\/article-pdf\/5\/14\/2799\/1813730\/advancesadv2021004575.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"http:\/\/ashpublications.org\/bloodadvances\/article-pdf\/5\/14\/2799\/1813730\/advancesadv2021004575.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,7,15]],"date-time":"2021-07-15T11:34:20Z","timestamp":1626348860000},"score":1,"resource":{"primary":{"URL":"https:\/\/ashpublications.org\/bloodadvances\/article\/5\/14\/2799\/476376\/CRP-and-ferritin-in-addition-to-the-EASIX-score"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,7,15]]},"references-count":28,"journal-issue":{"issue":"14","published-print":{"date-parts":[[2021,7,27]]}},"URL":"https:\/\/doi.org\/10.1182\/bloodadvances.2021004575","relation":{},"ISSN":["2473-9529","2473-9537"],"issn-type":[{"value":"2473-9529","type":"print"},{"value":"2473-9537","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,7,15]]}}}